Characterizing bat interferon stimulated genes as novel next generation therapy against highly pathogenic coronaviruses
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 493830
Grant search
Key facts
Disease
COVID-19, Middle East Respiratory Syndrome Coronavirus (MERS-CoV)start year
2023Known Financial Commitments (USD)
$220,676.51Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Banerjee ArinjayResearch Location
CanadaLead Research Institution
University of SaskatchewanResearch Priority Alignment
N/A
Research Category
Animal and environmental research and research on diseases vectors
Research Subcategory
Animal source and routes of transmission
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Bat species are being increasingly recognized as reservoirs of emerging viruses such as coronaviruses (SARS-CoV, SARS-CoV-2, and MERS-CoV), filoviruses (Ebola and Marburg virus), and paramyxoviruses (Nipah and Hendra viruses), among others. Bats that are naturally or experimentally infected with these viruses do not demonstrate clinical signs of disease, whereas other mammals, such as humans develop severe disease. We and others have shown that bat species have evolved a refined antiviral response which is characterized by: (1) low and controlled pro-inflammatory response, and (2) a robust interferon (IFN) mediated antiviral response. Type I IFNs are the first line of defence against invading viruses and they enact their effect by upregulating antiviral interferon stimulated genes (ISGs). Based on our previous studies, we will mechanistically characterize potent bat ISGs and develop top ranked ISGs as novel antiviral therapy against bat derived highly pathogenic human betacoronaviruses (beta-CoVs), such as MERS-CoV and SARS-CoV-2. We hypothesize that bat species have evolved ISGs that potently restrict beta-CoV replication and are resistant to inactivation by viral proteins. We will stimulate the production of ISGs in novel bat cell lines and in vivo in five species of bats (Eptesicus fuscus, Carollia perspicillata, Pteropus alecto, Rousettus aegyptiacus, and Eidolon helvum) that are known to carry viruses with human infection potential. We will characterize the 'interferome' in these bat species using bulk RNA sequencing and identify top ranked antiviral genes. Finally, we will generate recombinant bat ISGs and package them using lipid nanoparticle (LNP) technology to assess their antiviral efficacy against SARS-CoV-2 and MERS-CoV in vitro and in vivo. As multiple beta-CoVs with zoonotic potential currently circulate in bats, it is critical that we develop novel antiviral therapies to prevent the next pandemic.